Scarica l'app Stockscreener
26.85
0.71%
0.20
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARQT Giù?
Forum
Previsione
Precedente Chiudi:
$26.65
Aprire:
$26.41
Volume 24 ore:
261.23K
Relative Volume:
0.12
Capitalizzazione di mercato:
$3.29B
Reddito:
$59.61M
Utile/perdita netta:
$-262.14M
Rapporto P/E:
-6.8495
EPS:
-3.92
Flusso di cassa netto:
$-247.49M
1 W Prestazione:
+3.83%
1M Prestazione:
-8.43%
6M Prestazione:
+80.01%
1 anno Prestazione:
+97.35%
Intervallo 1D:
$26.09
$26.90
Intervallo di 1 settimana:
$25.12
$27.08
Portata 52W:
$11.13
$31.77
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Nome
Arcutis Biotherapeutics Inc
Settore
Industria
Telefono
805-418-5006
Indirizzo
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Confronta ARQT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
26.84 | 3.26B | 59.61M | -262.14M | -247.49M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.22 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.44 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
825.46 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
364.99 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.86 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-25 | Iniziato | Goldman | Neutral |
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-28 | Iniziato | Jefferies | Buy |
| 2024-01-03 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-10-26 | Downgrade | Mizuho | Buy → Neutral |
| 2023-10-13 | Downgrade | Goldman | Buy → Neutral |
| 2022-09-07 | Iniziato | Needham | Buy |
| 2022-03-17 | Iniziato | Goldman | Buy |
| 2021-06-30 | Iniziato | Mizuho | Buy |
| 2021-05-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-10-08 | Iniziato | Truist | Buy |
| 2020-02-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-02-25 | Iniziato | Cowen | Outperform |
| 2020-02-25 | Iniziato | Goldman | Neutral |
| 2020-02-25 | Iniziato | Guggenheim | Buy |
Mostra tutto
Arcutis Biotherapeutics Inc Borsa (ARQT) Ultime notizie
Arcutis To Present At Guggenheim Emerging Outlook Biotech Summit; Report Q4 Results In Feb - RTTNews
Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor Conference - The Manila Times
Arcutis Biotherapeutics : to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Invest - marketscreener.com
Arcutis to Report Fourth Quarter and Full Year 2025 Financial Results and Present at Upcoming Investor Conference - GlobeNewswire Inc.
Nationwide Survey Underscores Concerns with Use of Topical Steroids and Need for Long-Term Treatment Strategies Facing the 46 Million Americans with Chronic Inflammatory Skin Conditions - markets.businessinsider.com
Arcutis Biotherapeutics (ARQT) Reveals Insights on Steroid Use i - GuruFocus
Why 9 in 10 patients on steroid creams fear their skin treatment - Stock Titan
Published on: 2026-01-17 08:06:24 - baoquankhu1.vn
Is Arcutis Biotherapeutics Inc stock undervalued right nowMarket Weekly Review & Weekly Top Gainers Trade List - baoquankhu1.vn
Price-Driven Insight from (ARQT) for Rule-Based Strategy - Stock Traders Daily
Market Moves: Is Arcutis Biotherapeutics Inc stock good for income investorsPortfolio Update Report & Community Driven Trade Alerts - baoquankhu1.vn
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Unloaded Rep. Gilbert Ray Cisneros, Jr. - MarketBeat
Arcutis Biotherapeutics, Inc. (ARQT): Investor Outlook Reveals 18% Upside Potential - DirectorsTalk Interviews
Arcutis Biotherapeutics: Strengthening Zoryve Franchise, Approaching Profitability, and Multiple 2026+ Pipeline Catalysts Support Buy Rating - TipRanks
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 7.3%Here's What Happened - MarketBeat
Arcutis Biotherapeutics stock slides after 2026 ZORYVE sales outlook; June FDA deadline in focus - TechStock²
Arcutis highlights 2026 strategic priorities and anticipated milestones - marketscreener.com
Arcutis Highlights 2026 Strategic Priorities and Anticipated Milestones - The Manila Times
Skin drug maker maps 2026 plans, from infant trials to $470M sales - Stock Titan
Risk Recap: Is Arcutis Biotherapeutics Inc. stock a buy before product launchesMarket Movers & Fast Gaining Stock Reports - ulpravda.ru
Arcutis stock sinks 5% after wild swing as traders eye Fed, FDA clock and earnings - TechStock²
Earnings Report: Will Arcutis Biotherapeutics Inc. stock beat EPS estimatesJuly 2025 Rallies & Reliable Entry Point Trade Alerts - Улправда
How Arcutis Biotherapeutics Inc. stock compares to growth peersEarnings Overview Summary & Weekly Chart Analysis and Guides - ulpravda.ru
Is Arcutis Biotherapeutics Inc. stock a buy before product launchesMarket Movers & Fast Gaining Stock Reports - ulpravda.ru
Patrick Burnett Sells 2,490 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock - MarketBeat
Arcutis Bio EVP Burnett sells $72k in shares By Investing.com - Investing.com Canada
Arcutis Bio EVP Burnett sells $72k in shares - Investing.com
Arcutis Biotherapeutics, Inc.Common stock (NQ: ARQT - FinancialContent
Arcutis Biotherapeutics, Inc. (ARQT) Stock Analysis: Revenue Surge and Analyst Consensus Signal Opportunity - DirectorsTalk Interviews
Arcutis BiotherapeuticsFocusing On ZORYVE Market Expansion And Pipeline Growth - RTTNews
(ARQT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Arcutis Biotherapeutics (NASDAQ:ARQT) Raised to "Strong-Buy" at Wall Street Zen - MarketBeat
Arcutis Biotherapeutics CEO Todd Watanabe sells $245,122 in shares - MSN
Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells $49,552.40 in Stock - MarketBeat
Arcutis Biotherapeutics EVP Burnett sells $49,560 in shares By Investing.com - Investing.com South Africa
Arcutis Biotherapeutics EVP Burnett sells $49,560 in shares - Investing.com
Arcutis Biotherapeutics stock today: ARQT ends 2025 up 3.4% as traders eye FDA, earnings dates - TechStock²
Arcutis stock (ARQT) in focus after insider sale notice as U.S. markets shut for New Year’s Day - ts2.tech
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Up 3.4%Still a Buy? - MarketBeat
Arcutis Biotherapeutics stock pops today as ARQT bucks biotech dip into year-end trade - ts2.tech
Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Rating Lowered by Zacks Research - MarketBeat
Arcutis Biotherapeutics stock slides today as biotech pulls back, ARQT down nearly 3% - ts2.tech
Arcutis Biotherapeutics, Inc. (ARQT) Stock Analysis: A 10.73% Potential Upside Amidst Robust Revenue Growth - DirectorsTalk Interviews
Arcutis Biotherapeutics, Inc. $ARQT Shares Sold by Simplify Asset Management Inc. - MarketBeat
Arcutis Biotherapeutics Earnings Notes - Trefis
Arcutis Biotherapeutics (NASDAQ:ARQT) Downgraded by Wall Street Zen to Buy - MarketBeat
Is Suvretta’s Stake Cut and FDA’s Pediatric Review Acceptance Altering The Investment Case For Arcutis Biotherapeutics (ARQT)? - Yahoo Finance
Arcutis Stock Is Up 100% in a Year but Here’s Why One Fund Still Sold 1 Million Shares - Yahoo Finance
Arcutis Biotherapeutics Inc Azioni (ARQT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.34%
2.29%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):